Pfizer (New York) is voluntarily recalling metronidazole, ciprofloxacin, and ondansetron intravenous products because of the presence of floating matter and non-sterility discovered by the manufacturer Claris Lifesciences.
Pfizer (New York) is voluntarily recalling metronidazole, ciprofloxacin, and ondansetron intravenous (i.v.) products because of the presence of floating matter and non-sterility discovered by the manufacturer Claris Lifesciences (Ahmedabad, Gujarat, India). Pfizer made the announcement on June 3, following a recall initiated by Claris for all lots of the i.v. products metronidazole, ciprofloxacin, and ondansetron. These products were all manufactured on the same manufacturing line and sold under the Claris, Sagent Pharmaceuticals (Schaumburg, IL), Pfizer, and West-Ward Pharmaceuticals (Eatontown, NJ) labels.
Pfizer began distributing these Claris products to hospitals, wholesalers, and distributors in the US market this year under a licensing agreement with Claris. In 2009, Pfizer formed the agreement with Claris for the rights to 15 generic injectable drugs.
Pfizer is halting distribution of all sterile injectable products in i.v. bags licensed from Claris Lifesciences and is voluntarily recalling the products already distributed. Pfizer has distributed these products only in the US, according to Pfizer. The recall is being conducted with the knowledge of FDA. Of approximately 1.7 million i.v. bags licensed for distribution from Claris, approximately 1.3 million, or about 80%, currently remain in Pfizer’s control, according to Pfizer. Pfizer said it has received no customer reports of quality issues related to the i.v. bagged medicines from Claris Lifesciences.
All lots of the following products are affected by this recall:
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.